Oryzon's €37M Infusion: A Bet on Epigenetics and Mental Health's Future

MADRID and CAMBRIDGE, Mass. – July 01, 2026 – Oryzon Genomics, a Spanish biopharmaceutical firm at the forefront of epigenetic research, has secured a significant financial package totaling €37 million. The deal combines a freshly completed €12 million capital increase with a landmark €25 million investment commitment from COFIDES, Spain's state-owned development finance institution. This dual-pronged strategy is designed to accelerate the company’s advanced clinical programs in oncology and, notably, to channel significant resources into developing novel treatments for mental health disorders, an area of profound unmet medical need.

While the immediate market reaction saw a dip in the company's stock price, the move signals a confident, long-term strategy to translate its cutting-edge science into therapies for some of medicine's most challenging diseases. The financing not only strengthens Oryzon’s balance sheet but also provides powerful validation from a major public impact fund, potentially paving the way for future strategic partnerships.

A Calculated Move in a Jittery Market

Oryzon's €12 million capital raise was executed through the issuance of over 4.4 million new shares priced at €2.70 each. This figure represented a notable discount—14.15% against the five-day average price and 12.68% against the previous day's close. Such discounts are not uncommon in biotech capital raises, designed to attract swift investment, but they often trigger short-term market turbulence.

Indeed, following the announcement, Oryzon's stock experienced a decline of around 10% as investors reacted to the immediate dilution of their holdings and the discounted share price. The structure of the deal, a capital increase without pre-emptive rights for existing shareholders, further contributed to the sell-off. However, a closer look reveals a strategic calculus aimed at securing a robust financial runway.

Despite the short-term price pressure, analyst sentiment remains overwhelmingly positive. The consensus rating for Oryzon is a "Strong Buy," with an average 12-month price target suggesting a potential upside of over 120% from its current levels. This indicates that financial experts who follow the company closely view the capital raise as a necessary and ultimately value-creating step to fuel its high-potential pipeline. The proceeds are earmarked for advancing the clinical development of its lead cancer drug, iadademstat, progressing other programs, and strengthening the company's position for future partnership negotiations.

"This funding comes at a particularly important time for Oryzon and strengthens our ability to execute our clinical strategy with greater confidence," said Dr. Carlos Buesa, Chief Executive Officer of Oryzon. He noted that the progress of the company's acute myeloid leukemia program is "attracting increasing attention across the international oncology ecosystem." The capital, he explained, provides "financial flexibility to accelerate our priority programs while continuing to explore strategic opportunities that can maximize the value of our platform.”

The COFIDES Catalyst for Mental Health Innovation

Beyond the immediate capital injection, the more transformative element of the announcement is the agreement with COFIDES. Its Social Impact Fund has committed to invest €25 million in Oryzon's future capital increases over the next six months, acting as a powerful anchor investor. This commitment is not merely a financial transaction; it is a strategic endorsement tied to Spain's Recovery, Transformation and Resilience Plan, which is financed by the European Union's NextGenerationEU program.

This public-private partnership comes with a significant directive: at least 40% of the proceeds from the COFIDES investment must be allocated to developing medicines for unmet needs in mental health. This specifically targets Oryzon’s work on its lead central nervous system (CNS) drug, vafidemstat, for conditions like Borderline Personality Disorder (BPD). BPD is a severe psychiatric condition with limited effective treatment options, representing a major public health challenge.

The COFIDES backing serves as a powerful validation of Oryzon's scientific approach and its potential social impact. Dr. Buesa emphasized this point, stating, "The partnership with COFIDES' Social Impact Fund represents far more than a financial commitment; it is a recognition of the transformative potential of our mental health programs." He added that the validation from such a prestigious institution "reinforces our conviction that Oryzon can play a significant role in an area where unmet medical needs remain substantial." This institutional seal of approval is expected to enhance Oryzon's credibility, raise its international profile, and attract specialized global investment funds focused on life sciences and social impact.

Accelerating a Pioneer's Pipeline in Epigenetics

At its core, Oryzon is a science-driven company specializing in epigenetics—the study of how behaviors and environment can cause changes that affect the way genes work. Rather than altering the DNA sequence itself, epigenetic changes modify gene expression, and targeting these mechanisms offers a novel way to treat disease. The new funding will directly fuel the company's two lead programs, which are built on this pioneering science.

The first, iadademstat, is an inhibitor of an enzyme called LSD1 and is being developed for oncology. It has shown remarkable preliminary results in clinical trials for acute myeloid leukemia (AML), a particularly aggressive blood cancer. The company has reported a 100% overall response rate in a small cohort of first-line AML patients, a stunning figure that has captured the attention of oncologists and potential pharmaceutical partners. The €12 million raise will help accelerate this program's path through the clinic.

The second program, bolstered by the COFIDES agreement, is vafidemstat, another LSD1 inhibitor tailored for CNS disorders. It is Phase III-ready for BPD and is also being explored for other psychiatric conditions. The brain is a hotbed of epigenetic activity, and Oryzon's approach could offer a new paradigm for treating complex neurological and psychiatric illnesses that have seen little innovation in decades. The company is also advancing a broader pipeline, including a candidate targeting the HDAC6 enzyme for rare neurological disorders like Charcot–Marie–Tooth disease.

Positioning for a Strategic Future

This dual-funding success does more than just fill the company's coffers; it strategically repositions Oryzon within the broader biotech landscape. Securing €37 million in a challenging market, including a substantial commitment from a government-backed impact fund, signals resilience and long-term vision. This follows a successful €30 million equity raise in April 2025, demonstrating sustained investor confidence in its platform.

The company has been explicit that a key goal of this financing is to "support corporate development initiatives in anticipation of future partnership discussions." In the world of biotech, smaller, innovative companies often partner with large pharmaceutical giants to bring drugs through costly late-stage trials and to market. A stronger balance sheet and a de-risked pipeline, validated by both private investors and a public impact fund, make Oryzon a far more attractive partner.

By securing this capital, Oryzon gains leverage in any future negotiations, whether for licensing deals, co-development agreements, or a potential acquisition. The company is now better equipped to advance its programs independently, allowing it to negotiate from a position of strength and maximize shareholder value when the right strategic opportunity arises. This financial fortification ensures that its groundbreaking work in epigenetics has a clearer path from the laboratory to the patients who need it most.